Sienna Biopharmaceuticals, Inc. (SNNA) financial statements (2021 and earlier)

Company profile

Business Address 30699 RUSSELL RANCH ROAD, SUITE 140
WESTLAKE VILLAGE, CA 91362
State of Incorp. DE
Fiscal Year End December 31
SIC 2834 - Pharmaceutical Preparations (benchmarking)
More info Complete financial analysis Financial benchmarking

Balance sheet (Statement of financial position) ($ in millions)

9/30/2019
Q3
6/30/2019
Q2
3/31/2019
Q1
12/31/2018
Q4
9/30/2018
Q3
6/30/2018
Q2
3/31/2018
Q1
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments11495749647560
Cash and cash equivalents11495749647560
Restricted cash and investments0000000
Other undisclosed current assets8112332
Total current assets:20515950677862
Noncurrent Assets
Operating lease, right-of-use asset0  
Property, plant and equipment0000000
Intangible assets, net (including goodwill) 111111111112
Goodwill 111111111112
Other undisclosed noncurrent assets24464546464749
Total noncurrent assets:24575657585861
TOTAL ASSETS:43108115107125136124
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities1781114139
Accounts payable0223342
Accrued liabilities1345776
Employee-related liabilities0223322
Business combination, contingent consideration, liability 141514   
Other undisclosed current liabilities   0000
Total current liabilities:121222414139
Noncurrent Liabilities
Long-term debt and lease obligation 2929303030 
Long-term debt, excluding current maturities 2929303030 
Liabilities, other than long-term debt 302926353636
Deferred tax liabilities, net101011111111
Other liabilities 00    
Business combination, contingent consideration, liability 191916252524
Other undisclosed noncurrent liabilities19110112
Total noncurrent liabilities:19605956666738
Total liabilities:20818281808047
Stockholders' equity
Stockholders' equity attributable to parent23273327455676
Additional paid in capital210208207183181175173
Accumulated other comprehensive income1323447
Accumulated deficit(188)(184)(176)(159)(140)(123)(103)
Total stockholders' equity:23273327455676
TOTAL LIABILITIES AND EQUITY:43108115107125136124

Income statement (P&L) ($ in millions)

9/30/2019
Q3
6/30/2019
Q2
3/31/2019
Q1
12/31/2018
Q4
9/30/2018
Q3
6/30/2018
Q2
3/31/2018
Q1
Gross profit:0      
Operating expenses(6)(8)(16)(20)(17)(22)(18)
Other undisclosed operating loss(0)      
Operating loss:(6)(8)(16)(20)(17)(22)(18)
Nonoperating income (expense)(1)(1)(1)0(0)11
Other undisclosed loss from continuing operations before equity method investments, income taxes(2)      
Loss from continuing operations before income taxes:(9)(8)(16)(19)(17)(20)(17)
Income tax benefit5      
Net loss available to common stockholders, diluted:(4)(8)(16)(19)(17)(20)(17)

Comprehensive Income ($ in millions)

9/30/2019
Q3
6/30/2019
Q2
3/31/2019
Q1
12/31/2018
Q4
9/30/2018
Q3
6/30/2018
Q2
3/31/2018
Q1
Net loss:(4)(8)(16)(19)(17)(20)(17)
Other undisclosed comprehensive loss   (2)   
Comprehensive loss:(4)(8)(16)(22)(17)(20)(17)
Other undisclosed comprehensive income (loss), net of tax, attributable to parent(1)1(1)2(0)(2)1
Comprehensive loss, net of tax, attributable to parent:(5)(8)(17)(20)(17)(23)(16)

Statements sources

The financial statements are based on the company's filings with the The U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: